Introduction. Patients with CLL and FISH positive for trisomy 12 (+12) have unique clinical and biological features. We, therefore, performed an analysis of the association between demographic, clinical, laboratoristic and biological features and outcomes in treatment-naive patients with +12 CLL.

Methods. This study included 312 treatment-naive patients with +12 CLL from 9 centers. These patients, diagnosed between January 2000 and July 2016, were compared to a control group of 580 treatment-naive patients with FISH negative CLL, matched by age and gender and followed in the same centers. An additional cohort of 250 patients with +12 CLL followed at a single US institution was used as external validation.

Results. Patients' baseline characteristics are shown in Table 1. As compared to patients with negative FISH, patients with +12 had a significant higher prevalence of elevated LDH (p<0.001), elevated β-2-microglobulin (p<0.001), ZAP70 positivity (p<0.001), CD38 positivity (p<0.001), CD49d positivity (p<0.001) and unmutated IGHV (p<0.001). Among patients with +12, 206 (66%) progressed and 193 (62%) required treatment, 76 (24%) patients died and 28 (9%) deaths were attributed to CLL. Among patients with negative FISH, 260 (45%) progressed and 213 (37%) were treated, 97 (17%) patients died and 46 (8%) deaths were attributed to CLL progression. Patients with +12 CLL showed shorter survival in terms of progression free survival (PFS: 69 months vs 110 months, p<0.001), treatment free survival (TFS: 77 months vs 125 months, p<0.001) and overall survival (OS: 147 months vs 165 months, p=0.005). Clinico-biological factors associated with shorter PFS were found performing univariate analysis among +12 CLL patients. These data were confirmed also when using the external validation group of +12 patients for ZAP70 positivity (p=0.03), CD38 positivity (p=0.004), β-2-microglobulin levels (p<0.001) and Rai stage (p<0.001). Furthermore we divided our cohort of patients with +12 CLL according to LDH levels available at diagnosis: 73 patients showed levels above the normal limit many times and 149 patients had normal levels. High LDH levels resulted associated with a shorter PFS (37 months vs 73 months, p<0.001; Figure 1), shorter TFS (41 months vs 84 months, p<0.001), shorter OS (115 months vs 155 months, p=0.002) and shorter CLL-specific survival (134 months vs 179 months, p<0.001). This association was maintained on multivariable analyses both for PFS (hazard ratio [HR] 1.95, 95% confidence interval [CI] 1.3 to 3.0; p=0.002) and TFS (HR 1.81, 95% CI 1.1-3.0; p=0.025). LDH levels were also significantly correlated to OS (p<0.05) evaluating the events attributed to CLL.

Conclusions. In this large cohort analysis of 321 patients with +12 CLL, we were able to confirm that LDH levels above normal are common in this group and we observed that LDH levels independently predict a shorter PFS, TFS and CLL-specific survival in this population. LDH levels at diagnosis could allow to suspect trisomy 12 in CLL patients and predict different prognosis.

graphic
View largeDownload slide
graphic
View largeDownload slide
Disclosures

Coscia:Karyopharm: Research Funding; ROCHE: Honoraria, Other: Advisory board; Gilead: Honoraria; Mundipharma: Honoraria; Janssen: Honoraria. D'Arena:Janssen-Cilag: Honoraria. Reda:Gilead: Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees.

Topics:
chronic b-cell leukemias, chronic lymphocytic leukemia, progression-free survival, trisomy 12, therapy naive, zap-70 kinase, univariate analysis, cd38, disclosure

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2016 by The American Society of Hematology
2016
Sign in via your Institution